ARTICLE | Financial News
Epizyme falls on clinical hold
April 24, 2018 5:34 PM UTC
Epizyme Inc. (NASDAQ:EPZM) fell $2.30 (15%) to $13 in afternoon trading Tuesday after reporting late Monday that FDA placed a partial clinical hold on tazemetostat (E7438, EPZ-6438). The move shaved $160 million off the company’s market cap...
BCIQ Company Profiles
BCIQ Target Profiles